CN111225913B - 作为mglur4变构增强剂的吲唑化合物、组合物和治疗神经功能障碍的方法 - Google Patents
作为mglur4变构增强剂的吲唑化合物、组合物和治疗神经功能障碍的方法 Download PDFInfo
- Publication number
- CN111225913B CN111225913B CN201880067616.7A CN201880067616A CN111225913B CN 111225913 B CN111225913 B CN 111225913B CN 201880067616 A CN201880067616 A CN 201880067616A CN 111225913 B CN111225913 B CN 111225913B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- substituted
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| US62/546,290 | 2017-08-16 | ||
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111225913A CN111225913A (zh) | 2020-06-02 |
| CN111225913B true CN111225913B (zh) | 2024-05-31 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880067616.7A Active CN111225913B (zh) | 2017-08-16 | 2018-08-16 | 作为mglur4变构增强剂的吲唑化合物、组合物和治疗神经功能障碍的方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11427573B2 (enExample) |
| EP (1) | EP3668865A1 (enExample) |
| JP (1) | JP7253832B2 (enExample) |
| KR (1) | KR102687118B1 (enExample) |
| CN (1) | CN111225913B (enExample) |
| AU (1) | AU2018317403B2 (enExample) |
| BR (1) | BR112020003292A2 (enExample) |
| CA (1) | CA3072493A1 (enExample) |
| CL (1) | CL2020000360A1 (enExample) |
| CO (1) | CO2020002576A2 (enExample) |
| EA (1) | EA202090467A1 (enExample) |
| IL (1) | IL272575B2 (enExample) |
| PE (1) | PE20200756A1 (enExample) |
| SG (1) | SG11202001264UA (enExample) |
| UA (1) | UA128084C2 (enExample) |
| WO (1) | WO2019036534A1 (enExample) |
| ZA (1) | ZA202001321B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| PE20200756A1 (es) | 2017-08-16 | 2020-07-27 | Univ Vanderbilt | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica |
| US11427558B1 (en) | 2019-07-11 | 2022-08-30 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| EP4630419A1 (en) * | 2022-12-08 | 2025-10-15 | Boehringer Ingelheim International GmbH | Novel substituted pyrazine-carboxamide-imidazopyridine derivatives |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008061109A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| WO2008067121A2 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| CN102892288A (zh) * | 2010-02-11 | 2013-01-23 | 范德比尔特大学 | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法 |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017852B1 (ru) | 2006-12-20 | 2013-03-29 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные замещенных индазолов, активные в качестве ингибиторов киназ |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| US8658650B2 (en) | 2009-01-28 | 2014-02-25 | Vanderbilt University | Substituted 1,1,3,1-tetraoxidobenzo[D][1,3,2]dithiazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| SG177740A1 (en) | 2009-07-23 | 2012-02-28 | Univ Vanderbilt | Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
| US8779157B2 (en) | 2009-09-04 | 2014-07-15 | Vanderbilt University | MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112012009574A2 (pt) | 2009-10-22 | 2019-09-24 | Univ Vanderbilt | potencializador alostérico de mglura, composições, e métodos de tratamento de disfunção neurológica |
| AU2010314891A1 (en) | 2009-11-06 | 2012-06-07 | Vanderbilt University | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2011215645A1 (en) | 2010-02-11 | 2012-09-20 | Vanderbilt University | Benzisoxazoles and azabenzisoxazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| SG185414A1 (en) | 2010-05-12 | 2012-12-28 | Univ Vanderbilt | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| BR112016021626A2 (pt) | 2014-03-20 | 2018-05-15 | Samumed, Llc | indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| PE20200756A1 (es) | 2017-08-16 | 2020-07-27 | Univ Vanderbilt | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica |
-
2018
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt unknown
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008067121A2 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| WO2008061109A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| CN102892288A (zh) * | 2010-02-11 | 2013-01-23 | 范德比尔特大学 | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法 |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020531454A (ja) | 2020-11-05 |
| AU2018317403B2 (en) | 2023-09-21 |
| WO2019036534A1 (en) | 2019-02-21 |
| EA202090467A1 (ru) | 2020-06-18 |
| KR102687118B1 (ko) | 2024-07-19 |
| CA3072493A1 (en) | 2019-02-21 |
| EP3668865A1 (en) | 2020-06-24 |
| US10508105B2 (en) | 2019-12-17 |
| PE20200756A1 (es) | 2020-07-27 |
| US12291521B2 (en) | 2025-05-06 |
| SG11202001264UA (en) | 2020-03-30 |
| IL272575B1 (en) | 2023-05-01 |
| IL272575A (en) | 2020-03-31 |
| BR112020003292A2 (pt) | 2020-08-18 |
| US20220259190A1 (en) | 2022-08-18 |
| UA128084C2 (uk) | 2024-04-03 |
| AU2018317403A1 (en) | 2020-03-12 |
| IL272575B2 (en) | 2023-09-01 |
| ZA202001321B (en) | 2023-10-25 |
| US20190055225A1 (en) | 2019-02-21 |
| US20200291019A1 (en) | 2020-09-17 |
| JP7253832B2 (ja) | 2023-04-07 |
| US11427573B2 (en) | 2022-08-30 |
| CN111225913A (zh) | 2020-06-02 |
| CO2020002576A2 (es) | 2020-04-01 |
| KR20200054204A (ko) | 2020-05-19 |
| CL2020000360A1 (es) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111225913B (zh) | 作为mglur4变构增强剂的吲唑化合物、组合物和治疗神经功能障碍的方法 | |
| US10227343B2 (en) | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| CN102892288B (zh) | 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法 | |
| US9980945B2 (en) | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10221172B2 (en) | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| EP2533642A1 (en) | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | |
| US10526323B2 (en) | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10294222B2 (en) | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| MX2012005248A (es) | Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica. | |
| US11242342B2 (en) | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| US10968227B2 (en) | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| WO2019006157A1 (en) | Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| EA043291B1 (ru) | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |